Actively Recruiting
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
Led by Oxford Biodynamics Inc. · Updated on 2025-03-17
2000
Participants Needed
3
Research Sites
156 weeks
Total Duration
On this page
Sponsors
O
Oxford Biodynamics Inc.
Lead Sponsor
C
Community Clinical Oncology Research Network, LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.
CONDITIONS
Official Title
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Diagnosed with stage III or IV cancer
- Selected by healthcare provider to receive the Episwitch CiRT4 test as part of standard care
- ECOG performance status of 2 or less
- Clinically eligible for immune checkpoint inhibitor therapy
- Able to read, understand, and provide written informed consent
- Willing and able to follow study requirements
You will not qualify if you...
- Pregnant or breastfeeding
- History of bone marrow or organ transplant
- Contraindication for receiving immune checkpoint inhibitor therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Eastern Connecticut Hematology and Oncology
Norwich, Connecticut, United States, 06360
Actively Recruiting
2
Cancer Center of Middle Georgia
Dublin, Georgia, United States, 31021
Actively Recruiting
3
Carolina Blood and Cancer Care Associates
Rock Hill, South Carolina, United States, 29732
Actively Recruiting
Research Team
R
Ryan Mathis, MD
CONTACT
J
Joseph DeSimone, BA
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here